Literature DB >> 7131617

Phencyclidine intoxication: assessment of possible antidotes.

S Castellani, A J Giannini, J A Boeringa, P M Adams.   

Abstract

Phencyclidine (PCP), a widely abused drug currently, has multiple pharmacological actions, including psychotomimetic [1], anesthetic [2], sympathomimetic [2], anticholinergic [3-7], and dopaminergic [8-10]. Similarly, PCP intoxication in man can present with diverse symptoms: schizophrenia-like delusions and hallucinations; mania; violence, dyskinetic, catatonic, or stereotyped movements; hypertension; and coma [11, 12]. There is general agreement that the treatment of PCP intoxication includes support of vital functions and acidification of the urine [13]. However, there is no known specific antidote for PCP toxicity. Although diazepam [13], haloperidol [14, 15], and chlorpromazine [16] have been reported to improve the agitation and psychotic symptoms caused by PCP, the therapeutic efficacy of these agents has rarely been documented with objective clinical measures. Recently we found that intramuscular physostigmine and haloperidol [17, 18] improved several symptoms of acute PCP intoxication as measured by the Brief Psychiatric Rating Scale (BPRS) [19].

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7131617     DOI: 10.3109/15563658209025737

Source DB:  PubMed          Journal:  J Toxicol Clin Toxicol        ISSN: 0731-3810


  7 in total

1.  Clozapine Reverses Phencyclidine-Induced Desynchronization of Prefrontal Cortex through a 5-HT(1A) Receptor-Dependent Mechanism.

Authors:  Lucila Kargieman; Maurizio S Riga; Francesc Artigas; Pau Celada
Journal:  Neuropsychopharmacology       Date:  2011-10-19       Impact factor: 7.853

2.  Increased impulsivity and disrupted attention induced by repeated phencyclidine are not attenuated by chronic quetiapine treatment.

Authors:  Nurith Amitai; Athina Markou
Journal:  Pharmacol Biochem Behav       Date:  2008-09-08       Impact factor: 3.533

Review 3.  Recent progress in the synthesis and characterization of group II metabotropic glutamate receptor allosteric modulators.

Authors:  Douglas J Sheffler; Anthony B Pinkerton; Russell Dahl; Athina Markou; Nicholas D P Cosford
Journal:  ACS Chem Neurosci       Date:  2011-04-12       Impact factor: 4.418

Review 4.  Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia.

Authors:  Nurith Amitai; Athina Markou
Journal:  Biol Psychiatry       Date:  2010-05-21       Impact factor: 13.382

Review 5.  Glutamate and dopamine components in schizophrenia.

Authors:  Philip Seeman
Journal:  J Psychiatry Neurosci       Date:  2009-03       Impact factor: 6.186

6.  Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes.

Authors:  J M Stevenson; J L Reilly; M S H Harris; S R Patel; P J Weiden; K M Prasad; J A Badner; V L Nimgaonkar; M S Keshavan; J A Sweeney; J R Bishop
Journal:  Transl Psychiatry       Date:  2016-02-23       Impact factor: 6.222

7.  Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats.

Authors:  Nurith Amitai; Svetlana Semenova; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2007-05-12       Impact factor: 4.415

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.